Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner

Cancer Research

Volumn 74, Issue 19, 2014, Pages 5421-5434

  Volk Draper, Lisa ^a   Hall, Kelly ^a   Griggs, Caitlin ^a   Rajput, Sandeep ^a   Kohio, Pascaline ^a   DeNardo, David ^b   Ran, Sophia ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

BREAST NEOPLASMS; CHEMICALLY INDUCED; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; PACLITAXEL; TOLL-LIKE RECEPTOR 4;

EID: 84907484112     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0067     Document Type: Article

References (50)

1. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
2. O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013;138:829-37.
3. Kataja V, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2008;19:ii11-3.
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
5. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009;28:4353-63.
6. Daenen LG, Roodhart JM, van AM, Dehnad M, Roessingh W, et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 2011;71:6976-85.
7. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64.
8. Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013;12:1676-87.
9. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
10. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010;29:2242-52.
11. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-57.
12. Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer 2011;30:344-50.
13. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2010;60:217-26.
14. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, Del Casar JM, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010;10:665.
15. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011;71:1989-98.
16. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, et al. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010;16:2881-8.
17. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010;102:908-15.
18. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.
19. Tang XY, Zhu YQ, Wei B, Wang H. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci 2010;339:319-26.
20. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 2009;100:725-31.
21. Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest 2009;39:157-64.
22. Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med 2012;10:77.
23. Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, et al. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol 2012;10:193.
24. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16:1043-50.
25. van B Jr, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-9.
26. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, et al. Synergy of nabpaclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 2011;13:327-38.
27. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-35.
28. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, et al. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006;26:430-7.
29. Peinado H, Rafii S, Lyden D. Inflammation joins the "niche". Cancer Cell 2008;14:347-9.
30. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 2010;70:5728-39.
31. Volk-Draper LD, Rajput S, Hall KL, Wilber A, Ran S. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. Neoplasia 2012;14:926-42.
32. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
33. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102.
34. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-7.
35. Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, et al. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 2006;79:153-63.
36. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007;31:277-283.
37. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-8.
38. Voelcker V, Gebhardt C, Averbeck M, Saalbach A, Wolf V, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008;17:100-7.
39. Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum 2012;64:1477-87.
40. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-6.
41. Zheng H, Heiderscheidt CA, Joo M, Gao X, Knezevic N, et al. MYD88-dependent and -independent activation of TREM-1 via specific TLR ligands. Eur J Immunol 2010;40:162-71.
42. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
43. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of nonsmall-cell lung tumours after induction chemotherapy. Br J Cancer 2003;89:2184-9.
44. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, et al. Granulocytecolony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C +granulocytes. Proc Natl Acad Sci U S A 2010;107:21248-55.
45. Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001;15:156-65.
46. Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2009;17:229-51.
47. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315-20.
48. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63:1920-6.
49. Kang S, Lee SP, Kim KE, Kim HZ, Memet S, et al. Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages. Blood 2009;113:2605-13.
50. Ran S, Montgomery KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers 2012;4:618-57.